Search

Corvus Pharmaceuticals Inc

Ouvert

13.04 -4.4

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.06

Max

13.89

Chiffres clés

By Trading Economics

Revenu

-1.4M

-14M

BPA

-0.15

Employés

37

EBITDA

312K

-12M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+130.99% upside

Dividendes

By Acuity

Prochains Résultats

6 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-161M

1.2B

Ouverture précédente

17.44

Clôture précédente

13.04

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 juil. 2026, 23:52 UTC

Mexico's Q2 2026 GDP Growth Rate Release on July 30 Amid Cautious Economic Outlook and Market Volatility.

23 juil. 2026, 23:52 UTC

Germany's Inflation Rate Release on July 30, 2026 Sparks Market Speculation Amid Cooling Prices and Geopolitical Tensions.

23 juil. 2026, 23:52 UTC

Germany's July Inflation Rate Release Sparks Caution Among Investors Amid Rising Oil Prices and Geopolitical Tensions.

23 juil. 2026, 23:52 UTC

Japan's June inflation rises to 1.7%, but remains below Bank of Japan’s target, raising concerns over wage growth and global supply chain issues.

23 juil. 2026, 23:52 UTC

UK Consumer Confidence Index Improves to -17.0, Exceeding Expectations Amid Positive Market Sentiment and Geopolitical Concerns

23 juil. 2026, 23:52 UTC

Australia's S&P Global Manufacturing PMI rises to 51.7 in July, signaling continued growth amid inflationary pressures and increased hiring activity.

23 juil. 2026, 23:52 UTC

Australia's S&P Global Services PMI rises to 53.0 in July, signaling growth and boosting economic optimism despite global inflation concerns.

23 juil. 2026, 23:52 UTC

New Home Sales Expected at 610,000 Units Amid Rising Mortgage Rates and Declining Buyer Sentiment

23 juil. 2026, 23:52 UTC

Cautious Market Sentiment Ahead of U.S. New Home Sales Report Amid Rising Mortgage Rates and Declining Buyer Activity

23 juil. 2026, 23:52 UTC

Japan's Retail Sales Expected to Continue Growth Amid Strong Trade Data, but Inflation Concerns Loom Ahead of July 30 Release.

23 juil. 2026, 23:52 UTC

Japan's Industrial Production Faces Caution Ahead of July Release Amid Mixed Economic Signals and Rising Inflation.

23 juil. 2026, 23:52 UTC

The Nikkei 225 Index is trading lower in after-market hours, continuing its decline since Thursday. No specific news was identified to explain this move.

23 juil. 2026, 23:51 UTC

News

Cavco Industries Inc. announced its first-quarter earnings release date, contributing to positive investor sentiment. Shares are higher in after-market trading.

23 juil. 2026, 23:51 UTC

Woodward Inc. shares are lower in after-market trading, showing notable volatility with fluctuations between a high of 1.07% and a low of -1.01%.

23 juil. 2026, 23:51 UTC

Antero Resources Corp shares are higher in after-market trading, supported by rising crude oil prices amid inflation and interest rate concerns.

23 juil. 2026, 23:51 UTC

NewMarket Corp shares are lower in after-market hours, despite earlier gains. The stock is below its 20-day moving average amid inflation concerns.

23 juil. 2026, 23:51 UTC

Correlated Moves

Coeur Mining Inc shares are higher in after-market trading, aligning with a positive trend among gold-related equities amid broader market resilience despite bond market instability.

23 juil. 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

23 juil. 2026, 23:51 UTC

Under Armour Inc shares are lower in after-market trading, reflecting significant selling pressure despite broader market resilience amid inflation concerns and rising crude oil prices.

23 juil. 2026, 23:51 UTC

Southern Co. shares declined after-market, following a volatile session amid broader market resilience and concerns over inflation and rising crude oil prices.

23 juil. 2026, 23:51 UTC

News

Scholastic Corp shares fell in after-market trading following fourth-quarter results, where revenue of $476.1 million missed expectations and net income dropped to $9.4 million.

23 juil. 2026, 23:51 UTC

Trustmark Corp shares are lower in after-market hours, remaining below their 20-day moving average amid broader market instability reflected in rising credit default swaps.

23 juil. 2026, 23:51 UTC

News
Social Media

Leidos Holdings shares are lower in after-market trading amid concerns over long-term revenue growth, despite a backlog of $48.37 billion.

23 juil. 2026, 23:51 UTC

RPM International Inc shares are lower in after-market hours, reflecting notable weakness since Thursday's close and positioning below the 20-day moving average.

23 juil. 2026, 23:51 UTC

Array Technologies Inc. shares declined after-market, continuing a downward trend since Thursday's close, despite an earlier session rebound from a cumulative low.

23 juil. 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

23 juil. 2026, 23:51 UTC

Tyson Foods Inc shares are lower in after-market trading, remaining near the lower end of their one-month range amid broader market instability.

23 juil. 2026, 23:51 UTC

Spero Therapeutics Inc. shares are lower in after-market hours, continuing a downward trend after five consecutive sessions of declines.

23 juil. 2026, 23:51 UTC

Fidelity National Information Services shares are higher in after-market trading, despite earlier session declines and a lack of specific news to explain the movement.

23 juil. 2026, 23:51 UTC

American Water Works shares are higher in after-market trading, continuing positive momentum after three consecutive gains and positioning above the 20-day moving average.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

130.99% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD  130.99%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

5

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat